ENDRA Life Sciences Inc. (NDRA)

NCM – Цена в реальном времени. Валюта: USD

5.81

+0.74 (14.60%)

При закрытии: May 12, 2026, 4:00 PM EDT

5.78

+0.01 (0.17%)

До открытия: May 13, 2026, 4:00 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

ENDRA Life Sciences Inc. (NDRA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Видео

No Data

Пресс-релизы

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Search stocks

ENDRA Life Sciences Inc. (NDRA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Видео

No Data

Пресс-релизы

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use